Szczeklik A, Nizankowska E, Duplaga M
Dept of Medicine, Jagellonian University School of Medicine, Cracow, Poland.
Eur Respir J. 2000 Sep;16(3):432-6. doi: 10.1034/j.1399-3003.2000.016003432.x.
There is a subset of patients with bronchial asthma who are susceptible to disease exacerbation upon receiving aspirin and other nonsteroidal anti-inflammatory drugs. This is a clinical syndrome, called aspirin-induced asthma (AIA), associated with alterations in arachidonate metabolism and cysteinyl-leukotriene overproduction. The natural history and clinical characteristics of this type of asthma were studied. Sixteen clinical centres in 10 European countries provided standardized information to the specially developed patient-oriented database regarding: medical history, physical examination, diagnosis, and treatment. Diagnosis of AIA was based on a typical history, confirmed by positive aspirin provocation tests, carried out in 91% of the patients. A total of 500 patients were enrolled in the study. AIA developed according to a pattern, characterized by a sequence of symptoms. First, persistent rhinitis, appearing at a mean age of 29.7+/-12.5 yrs, then asthma, aspirin intolerance and nasal polyposis appear. The clinical presentation in different European countries was remarkably similar. In females, who outnumbered males by 2.3:1, the onset of symptoms occurred significantly earlier and the disease was more progressive and severe than in males. Atopy, present in approximately a third of patients, led to earlier manifestation of rhinitis and asthma, but not of aspirin intolerance or nasal polyposis. A family history of aspirin intolerance, recorded in 6% of patients, had a less evident effect on the course of the disease than sex or atopy. Fifty one per cent of patients, in addition to inhaled steroids, required chronic systemic corticosteroid therapy at a mean dose of 8 mg prednisone x day(-1). Surprisingly, 15% of patients were unaware of intolerance to aspirin and learnt about it only after having provocation tests performed. All over Europe, aspirin-induced asthma develops in a similar characteristic way. Its course is influenced by sex and the presence of atopy. In half of the patients, asthma is severe, and steroid-dependent. The uniform natural history of aspirin-induced asthma might suggest a common underlying principle.
有一部分支气管哮喘患者在服用阿司匹林和其他非甾体抗炎药后易出现病情加重。这是一种临床综合征,称为阿司匹林诱发的哮喘(AIA),与花生四烯酸代谢改变和半胱氨酰白三烯过度生成有关。对这类哮喘的自然病史和临床特征进行了研究。欧洲10个国家的16个临床中心向专门开发的以患者为导向的数据库提供了标准化信息,内容包括:病史、体格检查、诊断和治疗。AIA的诊断基于典型病史,并经阿司匹林激发试验阳性证实,91%的患者进行了该试验。共有500名患者纳入研究。AIA按照一种模式发展,其特点是一系列症状相继出现。首先是持续性鼻炎,平均发病年龄为29.7±12.5岁,随后出现哮喘、阿司匹林不耐受和鼻息肉。不同欧洲国家的临床表现非常相似。女性患者数量是男性的2.3倍,其症状出现明显更早,且疾病进展比男性更迅速、更严重。大约三分之一的患者存在特应性,这导致鼻炎和哮喘更早出现,但不会导致阿司匹林不耐受或鼻息肉更早出现。6%的患者有阿司匹林不耐受家族史,与性别或特应性相比,其对疾病进程的影响不太明显。51%的患者除吸入性类固醇外,还需要平均剂量为8毫克泼尼松/天的慢性全身皮质类固醇治疗。令人惊讶的是,15%的患者不知道自己对阿司匹林不耐受,只是在进行激发试验后才了解到这一点。在整个欧洲,阿司匹林诱发的哮喘以相似的特征方式发展。其病程受性别和特应性的影响。一半的患者哮喘严重且依赖类固醇。阿司匹林诱发哮喘统一的自然病史可能提示存在共同的潜在机制。